GH Research's (GHRS) Market Outperform Rating Reaffirmed at JMP Securities

JMP Securities restated their market outperform rating on shares of GH Research (NASDAQ:GHRS - Free Report) in a report published on Tuesday,Benzinga reports. JMP Securities currently has a $39.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of GH Research from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald initiated coverage on shares of GH Research in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of GH Research in a research report on Friday, May 9th. Guggenheim cut their price target on GH Research from $32.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Royal Bank Of Canada began coverage on shares of GH Research in a research report on Friday, March 7th. They set an "outperform" rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, GH Research presently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

GH Research Stock Down 1.3%

GHRS traded down $0.16 during trading on Tuesday, reaching $12.24. 38,210 shares of the company were exchanged, compared to its average volume of 191,112. The company's 50-day moving average is $11.30 and its two-hundred day moving average is $10.60. The company has a market cap of $636.64 million, a price-to-earnings ratio of -15.54 and a beta of 0.97. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.42. Equities analysts forecast that GH Research will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

Several hedge funds have recently made changes to their positions in GHRS. Cormorant Asset Management LP lifted its stake in shares of GH Research by 238.8% during the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock worth $22,165,000 after purchasing an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of GH Research in the 1st quarter valued at $8,272,000. Lynx1 Capital Management LP raised its stake in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after buying an additional 663,100 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in GH Research during the first quarter worth about $5,018,000. Finally, RA Capital Management L.P. boosted its position in GH Research by 3.9% in the 1st quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock worth $76,599,000 after purchasing an additional 257,959 shares in the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).